Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Tanaka, Kazuo; Nagao, Yumiko; Ide, Tatsuya; Kumashiro, Ryukichi; Sata, Michio

doi:10.3892/ijmm.17.5.827

Cited by 11 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, the studies included a total of 44,553 HBsAg-negative subjects, 9986 anti-HBc-positive and 34,567 anti-HBc-negative. Of the 26 studies included, 14 were conducted in Japan, [24,26,29,34,35,37–40,42–44,46,47] 5 in Italy, [27,30,36,41,45] 4 in the United States, [25,31,33] 1 each in Australia, [28] China, [49] and South Korea. [32] Fifteen studies enrolled patients with different stages of liver disease (chronic hepatitis or cirrhosis), [24,26,28,30,31,33,35–37,39,40,42,46,47,49] 2 studies involved patients with chronic hepatitis, [34,44] 5 studies patients with cirrhosis, [32,38,41,43,45] and 4 included also healthy controls.…”

Section: Resultsmentioning

confidence: 99%

“…Of the 26 studies included, 14 were conducted in Japan, [24,26,29,34,35,37–40,42–44,46,47] 5 in Italy, [27,30,36,41,45] 4 in the United States, [25,31,33] 1 each in Australia, [28] China, [49] and South Korea. [32] Fifteen studies enrolled patients with different stages of liver disease (chronic hepatitis or cirrhosis), [24,26,28,30,31,33,35–37,39,40,42,46,47,49] 2 studies involved patients with chronic hepatitis, [34,44] 5 studies patients with cirrhosis, [32,38,41,43,45] and 4 included also healthy controls. [25,27,29,48] The etiologic agent of liver disease was HCV in 18 studies, [24,28,29,31,33–37,39–47] alcohol in 2 studies, [32,38] primary biliary cirrhosis in 1, [49] whereas 5 studies [25–27,30,48] enrolled patients with a mixed etiology, HCV infection, alcohol abuse, and/or other nonspecified etiology.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease

Coppola¹,

Onorato²,

Sagnelli³

et al. 2016

Medicine

View full text Add to dashboard Cite

A meta-analysis was performed to ascertain to what extent hepatitis B surface antigen (HBsAg)-negative/anti-hepatitis B core (anti-HBc)-positive subjects with chronic liver disease are at a higher risk of developing hepatocellular carcinoma (HCC) than the anti-HBc-negative.All studies included had to fulfill the following characteristics and inclusion criteria: they investigated the relationship between HBsAg-negative/anti-HBc-positive serology and the occurrence of HCC, whether a case–control or cohort study, they provided relative risk (RR) or odds ratios (ORs) and 95% confidence intervals (CIs), were available as a full text written in English, and were published and indexed up to April 2015.Twenty-six original studies met the inclusion criteria, allowing a meta-analysis on 44,553 patients. The risk of HCC among the 9986 anti-HBc-positive subjects was 67% higher than in the 34,567 anti-HBc-negative (95% CI = 1.44–1.95, P < 0.0001). The results were similar when groups of patients with a different stage of liver disease (patients with chronic liver disease, patients with cirrhosis), with different ethnicity (Asian and non-Asian) and etiology (HCV and non-HCV) were considered. The risk of HCC was significantly higher in the 651 anti-HBs/anti-HBc-positive patients (RR = 1.36; 95% CI = 1.17–1.58, P = 0.03) and in the 595 anti-HBs-negative/anti-HBc-positive subjects (RR = 2.15; 95% CI = 1.58–2.92, P < 0.0001) than in the 1242 anti-HBs/anti-HBc negative. However, the RR from 8 studies indicated that the risk of HCC was 35% lower among the anti-HBs/anti-HBc-positive subjects compared to the anti-HBs-negative/anti-HBc-positive (RR = 0.65; 95% CI = 0.52–0.8, P < 0.0001).This meta-analysis shows that in HBsAg-negative subjects with chronic liver disease, anti-HBc positivity is strongly associated with the presence of HCC, an association observed in all subgroups according to the stage of the disease, etiology, and ethnicity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease

Coppola¹,

Onorato²,

Sagnelli³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…For example, past infection of hepatitis B virus (HBV) has been indicated as a major risk factor for the development of HCC in patients with chronic hepatitis C virus (HCV) infection [13][14][15][16][17][18][19]. However, whether a similar risk exists in patients with PBC is unknown, and the answers are of particular importance for the management of PBC in HBV endemic areas such as China [20,21].…”

Section: Introductionmentioning

confidence: 99%

Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis

Rong

Wang

Bowlus

et al. 2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The incidence, risk factors, and clinical features of hepatocellular carcinoma (HCC) in primary biliary cirrhosis (PBC) have been a long-standing subject of interest. We took advantage of a large cohort of 1865 well-defined Chinese patients with PBC for whom follow-up was conducted for up to 20 years to study the incidence of HCC. Our goal was to address the incidence and prevalence of HCC in PBC and the risk factors, including hepatitis B virus (HBV) infection, and finally to compare the tumor characteristics of PBC-related HCC, including size, location, mortality, and long-term outcomes, to that of HBV-related HCC. In this cohort, HCC occurred in 70 of 1865 PBC patients with a prevalence of 3.75 % and an incidence of 0.66 cases per 100 patient-years. The 5- and 10-year cumulative incidences were 2.6 % (95 % confidence interval (CI) 1.8-3.4) and 8.9 % (95 % CI 5.5-12.3), respectively. Age >54 years (odds ratio [OR] = 5.5, 95 % CI 3.0-10.1, p = 0.001), male sex (OR = 2.2, 95 % CI 1.2-4.0, p = 0.001), co-existence of diabetes mellitus (DM) (OR = 3.1, 95 % CI 1.6-6.2, p = 0.002), and previous HBV infection (OR = 6.6, 95 % CI 3.7-11.9, p = 0.001) were independently associated with the development of HCC. The tumor size, number, location, and 5-year survival were not significantly different in PBC-related HCC compared to HBV-related HCC. Alpha-fetoprotein was elevated in only 20 % of the cases with PBC-related HCC. Although HCC was uncommon, occurring in fewer than 5 % of patients, the risk is significantly increased by age, sex, DM, and past HBV infection.

show abstract

“…Through its effects on ZAP-70 the NS5A protein has a critical role in the initiation of T-cell signaling. Among patients with chronic HCV infection, including those who respond to interferon therapy, it is those that produce anti-HBc antibodies who are more likely to develop HCC, than those without anti-HBc (Tanaka et al, 2006). Viral hepatitis involves continuous interaction between the virus and the NF-kB-signaling system.…”

Section: Helicobacter Liver Infection and Nf-jb Signalingmentioning

confidence: 99%

NF-κB signaling, liver disease and hepatoprotective agents

2008

View full text Add to dashboard Cite

Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: A 12-year prospective study

Cited by 11 publications

References 36 publications

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease

Incidence and Risk Factors for Hepatocellular Carcinoma in Primary Biliary Cirrhosis

NF-κB signaling, liver disease and hepatoprotective agents

Contact Info

Product

Resources

About